{
    "clinical_study": {
        "@rank": "41958", 
        "arm_group": [
            {
                "arm_group_label": "BioChaperone insulin lispro", 
                "arm_group_type": "Experimental", 
                "description": "BioChaperone insulin lispro"
            }, 
            {
                "arm_group_label": "Humalog\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Humalog\u00ae"
            }
        ], 
        "brief_summary": {
            "textblock": "The addition of Biochaperone to insulin lispro may accelerate the onset and shorten the\n      duration of action of insulin lispro due to a facilitation of the absorption of the insulin\n      after subcutaneous injection.\n\n      The aim of the trial is to assess the efficacy and safety of BioChaperone insulin lispro in\n      subjects with Type 1 diabetes under a dose of 0.2 U/Kg.\n\n      This trial is a single-center, randomised, double-blinded, two-treatment, two-period\n      cross-over, 6-hour euglycaemic glucose clamp trial in subjects with Type 1 diabetes\n      mellitus. Each subject will be randomly allocated to a single dose of BioChaperone insulin\n      lispro 0.2 U/Kg and a single dose of Humalog\u00ae 0.2 U/Kg on 2 separate dosing visits."
        }, 
        "brief_title": "A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog\u00ae) in Subjects With Type 1 Diabetes", 
        "condition": "Diabetes Mellitus Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus for at least 12 months.\n\n          -  Treated with multiple daily insulin injections or insulin pump for at least 12\n             months.\n\n          -  Body Mass Index (BMI): 18.0-28.0 Kg/m\u00b2.\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus.\n\n          -  Receipt of any investigational product within 3 months prior to first dosing.\n\n          -  Clinically significant abnormalities as judged by the investigator.\n\n          -  Any systemic treatment with drugs known to interfere with glucose metabolism.\n\n          -  History of alcoholism, or drug/chemical abuse as per Investigator's judgement.\n\n          -  Use of tobacco or nicotine-contained product within 5 years prior to screening.\n\n          -  Blood or plasma donation in the past month or more than 500 mL within 3 months prior\n             to screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029924", 
            "org_study_id": "BC3-CT006"
        }, 
        "intervention": [
            {
                "arm_group_label": "BioChaperone insulin lispro", 
                "description": "Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)", 
                "intervention_name": "BioChaperone insulin lispro", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Humalog\u00ae", 
                "description": "Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)", 
                "intervention_name": "Humalog\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Grit Andersen, MD", 
                "phone": "+49 2131 4018-0"
            }, 
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog\u00ae) in Subjects With Type 1 Diabetes", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Area under the curve of the insulin lispro concentration - time curve from 0 to 30 minutes", 
            "measure": "Area under the curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029924"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to first observed half maximum observed insulin lispro concentration", 
                "measure": "Pharmacokinetics: Early t0.5max(Lisp)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 hours post administration of study drug"
            }, 
            {
                "measure": "Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 6 hours", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "description": "Time to first observed half maximum glucose infusion rate", 
                "measure": "Glucodynamics: Early t0.5(GIRmax)", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Glucodynamic: GIRmax (Maximum glucose infusion rate)", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the insulin lispro serum concentration. Time curve from t=0 to 6 hours", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Pharmacokinetics: tmax(Lisp) - Time from t=0 hours to maximum observed insulin lispro concentration", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Adocia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adocia", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}